Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alternaria alternata allergen extract is a biological product derived from the common mold *Alternaria alternata*. It is used for both the diagnosis and treatment of allergies to this fungus, which are a significant cause of respiratory conditions like allergic rhinitis and asthma. For diagnosis, the extract is used in skin prick tests and bronchial challenges to identify sensitivity in patients. As a therapeutic, it is the active component in allergen-specific immunotherapy (AIT), which aims to desensitize the patient's immune system. This immunotherapy works by administering controlled doses of the allergen, either via subcutaneous injection or sublingually, to modulate the immune response and build tolerance. To improve safety and reduce the high rate of adverse reactions associated with native extracts, modified versions called allergoids are developed. These are often created by treating the native extract with substances like glutaraldehyde, which polymerizes the proteins, reducing their ability to bind to IgE while retaining their immunogenicity. These polymerized extracts, such as Clustoid MAX Alternaria and Depigoid Alternaria alternata, allow for safer administration at higher concentrations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alternaria alternata allergen extract.